A specialty pharmaceutical company focused on hospital/acute care settings, developing non-opioid products for acute pain and neuromuscular blockers and related compounds for rapid induction and reversal of neuromuscular blockade. Recro’s acute pain products include meloxicam IV, a proprietary, long-acting treatment for moderate to severe pain and Dex-IN, a proprietary intranasal form of dexmedetomidine, for peri-procedural pain. In 2H 2017, Recro submitted the New Drug Application for meloxicam IV and are currently in discussions with FDA regarding the safety and effectiveness of the product.